White Pine Capital LLC Acquires 542 Shares of Kenvue Inc. (NYSE:KVUE)

White Pine Capital LLC increased its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 1.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,572 shares of the company’s stock after buying an additional 542 shares during the period. White Pine Capital LLC’s holdings in Kenvue were worth $1,165,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Vontobel Holding Ltd. lifted its stake in Kenvue by 38.7% in the fourth quarter. Vontobel Holding Ltd. now owns 31,335 shares of the company’s stock valued at $669,000 after buying an additional 8,741 shares during the period. Asset Management One Co. Ltd. increased its stake in shares of Kenvue by 3.0% in the 4th quarter. Asset Management One Co. Ltd. now owns 749,580 shares of the company’s stock valued at $16,138,000 after acquiring an additional 21,545 shares during the last quarter. Pathway Financial Advisers LLC raised its position in shares of Kenvue by 19.1% in the 4th quarter. Pathway Financial Advisers LLC now owns 12,697 shares of the company’s stock valued at $271,000 after acquiring an additional 2,040 shares during the period. Avestar Capital LLC acquired a new stake in shares of Kenvue in the 4th quarter valued at approximately $215,000. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in Kenvue during the 4th quarter worth approximately $128,000. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Up 2.4 %

NYSE:KVUE opened at $21.47 on Friday. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The firm has a market capitalization of $41.15 billion, a price-to-earnings ratio of 40.50, a price-to-earnings-growth ratio of 2.16 and a beta of 1.45. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock’s 50 day moving average price is $21.37 and its two-hundred day moving average price is $22.03.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities research analysts expect that Kenvue Inc. will post 1.05 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be issued a $0.205 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.82%. Kenvue’s payout ratio is 154.72%.

Wall Street Analysts Forecast Growth

KVUE has been the subject of several recent analyst reports. Citigroup lowered their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research note on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $21.00 to $26.00 in a report on Monday, January 6th. Bank of America increased their price target on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $23.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.